Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Florence Ader"'
Autor:
Oana Dumitrescu, Hélène Labussière-Wallet, Claire Triffault-Fillit, Elisabeth Hodille, Sandrine Roux, Sarah Soueges, Isabelle Morelec, Florence Ader, David Lebeaux
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 40:2033-2036
Nocardiosis is a life-threatening opportunistic infection in immunocompromised patients. Herein, we present successful adjunctive use of liposomal nebulized amikacin and tedizolid in a recipient of allogeneic hematopoietic stem cell transplantation i
Autor:
F. Wallet, Laurent Argaud, Florence Persat, Jean Turc, Jean Menotti, Jean-Christophe Richard, Charline Miossec, Martine Wallon, Damien Dupont, S. Paulus, Florence Ader
Publikováno v:
Medical Mycology
Medical Mycology, 2021, 59 (1), pp.110-114. ⟨10.1093/mmy/myaa078⟩
Medical Mycology, Oxford University Press, 2021, 59 (1), pp.110-114. ⟨10.1093/mmy/myaa078⟩
Medical Mycology, 2021, 59 (1), pp.110-114. ⟨10.1093/mmy/myaa078⟩
Medical Mycology, Oxford University Press, 2021, 59 (1), pp.110-114. ⟨10.1093/mmy/myaa078⟩
Occurrence of putative invasive pulmonary aspergillosis was screened in 153 consecutive adult intensive care unit (ICU) patients with respiratory samples addressed for mycological diagnosis during a 6-week period at the emergence of coronavirus disea
Autor:
Stanislas Faguer, Pierre Tiberghien, Etienne Crickx, Fanny Pommeret, David Veyer, Claire Rouzaud, Fabrice Camou, Olivier Hermine, Elie Azoulay, Pierre Gallian, Cécile Pouderoux, Deborah Eshagh, Jonathan London, Fatiha Merabet, Philippe Petua, David Boutboul, Laure Anne Raillon, Valérie Zeller, Hélène Péré, Benjamin Planquette, Jérôme Pacanowski, Adrien Joseph, Marc Michel, Martin Martinot, Matthieu Mahévas, Lucienne Chatenoud, Karine Lacombe, Anne Lise Beaumont, David Ghez, Amani Ouedrani, Tali Anne Szwebel, Arsène Mekinian, Florence Ader, Thomas Hueso, Marc Garnier, Sébastien Clerc
Publikováno v:
Blood
There is a Blood Commentary on this article in this issue.
Key Points As a proof of concept, COVID-19 convalescent plasma represents an interesting approach in B-cell–depleted patients with protracted COVID-19.COVID-19 convalescent plasma indu
Key Points As a proof of concept, COVID-19 convalescent plasma represents an interesting approach in B-cell–depleted patients with protracted COVID-19.COVID-19 convalescent plasma indu
Autor:
Oana Dumitrescu, Stéphane Dray, Emilie Westeel, Jean-Luc Berland, Alexia Barbry, Gerard Lina, Laurent Jacob, Elisabeth Hodille, Samuel Venner, Charlotte Genestet, Florence Ader, François Massol, Guislaine Refrégier
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) complex, is still the number one deadly contagious disease. Mtb infection results in a wide spectrum of clinical presentations and severity symptoms, but without proven Mtb genetic determi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94135bf1db6a0c1738f52e6e705b1b2b
https://hal.science/hal-03433572
https://hal.science/hal-03433572
Autor:
Vincent Dubée, Bernard Vanhove, Benjamin Gaborit, Alexandra Jobert, Richard Danger, Sophie Brouard, Florence Ader, Régis Josien, Virginie Ferré, Laurent Flet, Marie-Anne Vibet, Laetitia Berly, Eric Dailly, Anne Omnes, Anne Chiffoleau, Aurélie Le Thuaut, François Raffi, Karine Lacombe, Odile Duvaux
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2021, 65 (9), ⟨10.1128/AAC.01237-21⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2021, 65 (9), ⟨10.1128/AAC.01237-21⟩
We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related moderate pneumonia. The objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b66a7030b38640ac0ec955abba032dcc
https://hal.archives-ouvertes.fr/hal-03378960
https://hal.archives-ouvertes.fr/hal-03378960
Autor:
Sylvain Goutelle, Gerard Lina, Charlotte Genestet, Alexia Barbry, Jonathan Hoffmann, Jean-Luc Berland, Christophe Ginevra, Emilie Westeel, Florence Ader, Elisabeth Hodille, Fabiola Bastian, Samuel Venner, Michel Guichardant, Oana Dumitrescu
Publikováno v:
PLoS Pathogens
PLoS Pathogens, 2021, 17 (6), pp.e1009643. ⟨10.1371/journal.ppat.1009643⟩
PLoS Pathogens, Vol 17, Iss 6, p e1009643 (2021)
PLoS Pathogens, 2021, 17 (6), pp.e1009643. ⟨10.1371/journal.ppat.1009643⟩
PLoS Pathogens, Vol 17, Iss 6, p e1009643 (2021)
Mycobacterium tuberculosis (Mtb) genetic micro-diversity in clinical isolates may underline mycobacterial adaptation to tuberculosis (TB) infection and provide insights to anti-TB treatment response and emergence of resistance. Herein we followed wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3cf23f66032a1f7a3b76194da5afd4
https://hal.inrae.fr/hal-03528437
https://hal.inrae.fr/hal-03528437
Autor:
Rémi Pescarmona, Anne Conrad, Bruno Lina, Martine Valette, Sylvie Pons, Vanessa Escuret, Tristan Ferry, Christelle Compagnon, Geneviève Billaud, Maude Bouscambert, Florent Valour, Christine Lombard, William Mouton, Pierre Lecam, Sandrine Roux, Fabienne Venet, Patrick Miailhes, Valérie Cheynet, Claire Triffault-Fillit, Sophie Trouillet-Assant, Pierre Chauvelot, Marine Villard, Clément Munier, Louis Chauvelot, Sébastien Viel, Guillaume David, Emilie Frobert, Agathe Becker, Laure Folliet, Lorna Garnier, Laurent Bitker, Paul Chabert, Florence Ader, Alexandre Gaymard, Jean-Christophe Richard, Grégory Destras, Laurence Josset, Magali Perret, Antonin Bal, Karen Brengel-Pesce, Guy Oriol, Thomas Perpoint, Laurence Generenaz, Cécile Pouderoux, Florence Morfin, Marielle Perry, Mehdi Mezidi, Christian Chidiac, Yonis Hodane, Judith Provoost, Nicholas Benech, Alexandre Belot, Thierry Walzer
Publikováno v:
Journal of Allergy and Clinical Immunology
Journal of Allergy and Clinical Immunology, 2020, 146, pp.206-208.e2. ⟨10.1016/j.jaci.2020.04.029⟩
Journal of Allergy and Clinical Immunology, Elsevier, 2020, 146, pp.206-208.e2. ⟨10.1016/j.jaci.2020.04.029⟩
Journal of Allergy and Clinical Immunology, 2020, 146, pp.206-208.e2. ⟨10.1016/j.jaci.2020.04.029⟩
Journal of Allergy and Clinical Immunology, Elsevier, 2020, 146, pp.206-208.e2. ⟨10.1016/j.jaci.2020.04.029⟩
International audience; No abstract available
Autor:
Anne Bergeron-Lafaurie, Anne-Gaëlle Ranc, Nicolas Magand, Cécile Pouderoux, Florence Ader, Ghislaine Descours, Laetitia Beraud, Anne Conrad, S. Jarraud, Sandrine Boisset, Christophe Ginevra
Publikováno v:
Clinical Infectious Diseases. 70:1933-1940
Background Rarely, Legionnaires’ disease (LD) can progress into a slowly or nonresolving form. Methods A nationwide retrospective study was conducted by the French National Reference Center for Legionella (2013–2017) including cases of slowly or
Autor:
Nicolas, Benech, Oana, Dumitrescu, Anne, Conrad, Marie, Balsat, Etienne, Paubelle, Sophie, Ducastelle-Lepretre, Hélène, Labussière-Wallet, Gilles, Salles, Sabine, Cohen, Sylvain, Goutelle, Florence, Ader, M, Wallon
Publikováno v:
Journal of Antimicrobial Chemotherapy. 74:2676-2680
Objectives To assess population pharmacokinetics (PK) and pharmacodynamics (PD) of both piperacillin and tazobactam in neutropenia patients and examine dosage requirements related to the MIC distribution for Gram-negative bacteria involved in bloodst
Autor:
Benjamin Gaborit, Bernard Vanhove, Marie-Anne Vibet, Aurélie Le Thuaut, Karine Lacombe, Vincent Dubee, Florence Ader, Virginie Ferre, Eric Vicaut, Jéremie Orain, Morgane Le Bras, Anne Omnes, Laetitia Berly, Alexandra Jobert, Pascale Morineau-Le Houssine, Karine Botturi, Régis Josien, Laurent Flet, Nicolas Degauque, Sophie Brouard, Odile Duvaux, Alexandra Poinas, François Raffi, POLYCOR study group
Publikováno v:
Trials
Trials, 2021, 22 (1), pp.199. ⟨10.1186/s13063-021-05132-9⟩
Trials, BioMed Central, 2021, 22 (1), pp.199. ⟨10.1186/s13063-021-05132-9⟩
Trials, Vol 22, Iss 1, Pp 1-17 (2021)
Trials, 2021, 22 (1), pp.199. ⟨10.1186/s13063-021-05132-9⟩
Trials, BioMed Central, 2021, 22 (1), pp.199. ⟨10.1186/s13063-021-05132-9⟩
Trials, Vol 22, Iss 1, Pp 1-17 (2021)
Background Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach. Polyclonal neutralizing antibodies offers many advantages such as providing immediate i